Allogeneic CAR Cell Therapies: The Rise of Off-the-Shelf Immunotherapy

Key Takeaways

Allogeneic CAR therapies enable off-the-shelf cancer immunotherapy, offering faster treatment availability, scalable manufacturing, and broader patient access compared with autologous CAR-T.
Advanced gene-editing technologies (e.g., CRISPR and TALEN) are central to improving safety, persistence, and efficacy while reducing graft-versus-host disease and immune rejection.
Multiple immune cell platforms, including CAR-NK, NKT, γδ T, and iPSC-derived cells, are expanding the therapeutic landscape, especially for solid tumors and non-oncology indications.
Key barriers to commercialization include manufacturing scalability, cell sourcing variability, immune compatibility, and regulatory complexity, which continue to limit clinical success relative to autologous therapies.
Market growth and rising clinical activity signal strong industry momentum, with hundreds of trials underway and manufacturing projected to expand rapidly despite the field’s early-stage maturity.

Why Allogeneic CAR Cell Therapies?

Chimeric antigen receptor (CAR)-T cell therapies have advanced cancer treatment for hematological malignancies and, for many of the patients lucky enough to receive them, have provided improved quality of life and often much longer lifetimes. However, the CAR-T therapies approved to date are all autologous, or patient-specific, and come at a very high cost due to logistic and manufacturing complexities and challenges. Many patients do not qualify, and for those that do, access is often limited, and some patients are too sick to survive the week-long wait time between diagnosis and treatment administration.^1–4

Allogeneic CAR therapies have the potential to overcome many of the factors hindering widespread application of adoptive cell therapy for cancer and other diseases. In addition to simpler logistics and manufacturing, these off-the-shelf therapies are derived from healthy donor cells with less variability and are immediately available for patients and can be genetically engineered to potentially offer better safety and efficacy.^2–5 They may thus be appropriate for many more patients than autologous therapies and more accessible due to reduced costs.

What Cell Types are Suitable?

In addition to traditional T cells for immunotherapy, allogenic CAR treatments can be developed from a range of cell types, including other immune cells such as natural killer (NK), invariant natural killer T (NKT), gamma delta T (γδ T) cells, and macrophages.^1,2,4,5 Sources of these cells can include donated peripheral blood mononuclear cells (PBMCs), cord blood cells, and stem cells, such as induced pluripotent stem cells (iPSCs) and hematopoietic stem and progenitor cells (HSPCs).

PBMCs require disruption of endogenous T cell receptors (TCRs) through gene editing to avoid graft-versus-host disease (GvHD). NK cells are attractive because they do not cause GvHD. iPSCs may have the greatest potential to serve as consistent sources for scalable allogeneic CAR therapies as they can be differentiated into most types of cells, including T and NK cells.

What Types of Genetic Engineering are Used?

Advances in gene editing are one of the greatest drivers for allogeneic CAR cell therapy development activity.³ Gene editing is used not only to enhance signaling and improve therapeutic efficacy. It is also important in reducing off-target activity and cell exhaustion and enabling the engineering of allogenic products that do not cause GvHD and exhibit reduce immune rejection.¹ Examples of CAR constructs with improved safety, durability, and specificity, including against solid tumors, include bispecific CARs, logic-gated CARs, the synthetic TCR and antigen receptor (STAR) platform, and products containing inducible suicide switches to reduce risk of cytokine release syndrome (CRS) and neurotoxicity. Specific gene editing technologies that have been used in allogenic CAR therapy development include CRISPR-Cas9 and TALEN.

What Allogeneic Cell Therapies are in the Clinic?

Multiple types of allogeneic CAR therapies are under investigation in clinical trials, with most at early phases. Candidates include those derived from healthy donor PBMCs (CAR-T and CAR-NKT), as well as cord blood–derived and iPSC-engineered CAR-NKs.¹ Most clinical trials involve CAR-T cell therapies, followed by CAR-NK and CAR-γδ T treatments. Most are cancer therapies for hematological cancers (targeting CD19⁺ B cell malignancies and BCMA⁺ MM), although several are in development against solid tumors including hepatocellular carcinoma, lung cancer, and ovarian cancer. Other antigens targeted by allogenic CAR therapies include CD22, CD7, and CD70, and some employ dual targeting.⁴ Outside of cancer, other autoimmune and infectious disease targets predominate.

What is Happening at the Preclinical Development Stage?

Preclinical research in the allogeneic CAR therapy space is largely focused on exploring new cell types, applying novel genetic engineering approaches, and improving manufacturing technologies.¹ In addition to CAR-NK, CAR-NKT, and CAR-γδ T cells, CAR–mucosal-associated invariant T (MAIT) cells are attracting attention because there is no concern for GvHD with these cell types and because they also have different tumor-killing mechanisms than regular T cells. The challenge is the low percentage of these types of cells in peripheral blood. That is driving research into the differentiation of iPSCs and the engineering of HSPCs to generate CAR-NKT cells for use in allogenic CAR therapies. CAR-γδ T cells are also of interest because they recognize infected or malignant cells independent of MHC attributes. CAR-MAIT therapies have been shown in preclinical studies to exhibit strong cytotoxicity against ovarian cancer cells and the potential to not only attack tumor cells but also modulate the tumor microenvironment (TME).

What Important Hurdles to Allogeneic Cell Therapy Remain?

Just as is the case with any immature therapeutic modality, the development and manufacture of optimal allogenic CAR therapies face significant hurdles that must be surmounted before the field can reach its full potential for improving the lives of patients in need.^1,4,5

In addition to the challenges of GvHD owing to the use of donor-derived cells recognizing host cells as foreign and immune rejection leading to insufficient persistence, allogeneic CAR therapy developers must solve numerous manufacturing issues (most notably related to cell sourcing and scalability) to increase efficiency and reduce cost and navigate regulatory uncertainties and evolving guidance as the field matures.

Common strategies for minimizing GvHD include genetic engineering cells to knockout TCRs, HLA matching, and the use of cell types with a reduced risk for GvHD. To reduce immune rejection, cells are engineered for reduced cytokine signaling, deletion of HLA-I and HLA-II molecules, and overexpression of certain ligands that interfere with antibody-mediated clearance, among other changes designed to minimize attacks by the host immune system. Such modifications must be done carefully, as not only is achieving efficient and accurate multiplex gene editing difficult, but extensive genetic engineering can lead to negative consequences, including chromosomal aberrations, off-target effects, and genomic instability.

With respect to cell sourcing, ethical issues around informed donor consent and cell banking must be addressed. Of particular note is umbilical cord blood, which is collected at birth under parental consent but often without full knowledge of the future intended use. There is also some concern about the need for matched donors limiting access to novel allogenic therapies. Batch-to-batch variability due to differences in donor genetics, immune status, phenotype, cytokine production, expansion potential, and overall cell quality resulting from differences in age, health status, cultural background/diet, and other factors is yet another issue that must be addressed.

Moving allogeneic CAR therapy production processes from the lab to the clinic and then commercial production presents numerous challenges as well. Most cell types used in allogenic CAR therapies are sensitive to shear stress and the changing conditions within bioreactors. Maintaining cell quality and viability can thus requires careful design and control of processes, which also must overcome variability due to differences in donor cells. Using iPSCs can help increase standardization, but this approach requires more upfront time and investment.

Separately, production of the lentiviral vectors used to introduce CARs is costly and time consuming, and significant work is still needed to improve the efficiency of these processes. There is considerable research into nonviral delivery methods as a result. The need for additional cell type–dependent gene editing to address GvHD, persistence, and other issues adds further complexity, cost, and risk. Maintaining the proper phenotype and functionality throughout the large number of passages required to achieve sufficient cell mass is yet another challenge. Finally, developing cryopreservation processes that do not impact cell viability and functionality is not a simple task.

What are Some Exciting Recent Examples?

Despite these challenges, real progress is being made toward the commercialization of allogeneic CAR therapies. Researchers at the University of Texas MD Anderson Cancer Center developed ALLO-316, an allogeneic CAR-T cell therapy that targets CD70⁺ tumor and host T cells (for reduced allorejection).⁶ When administered in a trial involving 44 heavily pretreated patients with clear cell renal cell carcinoma, only one infusion demonstrated manageable safety and encouraging antitumor activity.⁶

Different researchers at MD Anderson have developed the PreCISE CRISPR screening tool for primary human NK cells, which helps determine which gene targets should be removed to improve cell function and persistence.⁷ The allogeneic CAR-NK therapy CD19 t-haNK (ImmunityBio) is an NK-92–based cell therapy genetically engineered to express a CD19-specific CAR and a high-affinity CD16 (FcγRIIIa 158V) receptor.⁸ It is being investigated in combination with the monoclonal antibody rituximab and the chemotherapy ANKTIVA for treatment of indolent non-Hodgkin lymphoma (iNHL). CD19 t-haNK has been shown to provide durable complete responses with rituximab alone. Adding ANKTIVA is anticipated to enhance NK and T cell activity and potentially overcome tumor resistance to rituximab.

Meanwhile, scientists at UCLA modified NKT cells to increase their selectivity for ovarian cancer cells, which are challenging because they are very heterogeneous and exist in a highly immunosuppressive TME, by identifying up to 12 molecular markers. The therapy is designed to attack both the tumor cells and immunosuppressive cells in the TME.⁹ The therapy was tested against 35 ovarian patient-derived tumor samples, and it killed the cells in all the samples, which came from a mix of newly diagnosed patients and patients with cancer that recurred after chemotherapy.

In a different approach, researchers at Memorial Sloan Kettering Cancer Center developed an allogeneic CAR-T cell therapy for treatment of relapsed or refractory B cell malignancies using Epstein-Barr virus (EBV)-specific T cells (EBV-VSTs) genetically modified with a CD19-specific CAR (19-28z).¹⁰ In a clinical study, patients received on average 2.5 doses, with no dose-limiting toxicity, severe CRS, or neurotoxicity observed. After 12 and 36 months, respectively, 81% and 75% of patients still survived.

In addition, more than 20 clinical studies investigating allogeneic CAR-NK and CAR-T cell therapies against relapsed/refractory (r/r) large B-cell lymphoma (LBCL) have obtained promising results with respect to both safety and efficacy in heavily pretreated patients.¹¹

What’s Next for Allogeneic Cell Therapy?

While selected investigational allogeneic CAR cell therapies show promise in the lab and early clinical studies, none has yet received marketing authorization and many have failed to provide results comparable to autologous treatments.⁵ The biggest issue, it seems, is persistence. Consequently, allogeneic CAR therapies have shown greater promised for treatment of autoimmune diseases, where persistence is not essential.

Even so, more efforts are being directed toward the development of allogeneic CAR-T, mesenchymal stem cell (MSC), and CRISPR-based therapies than autologous products due to the potential for simpler logistics, scalable manufacturing, on-demand availability, and lower cost.¹²

The value of the global cell therapy market is projected to expand at a compound annual growth rate (CAGR) of just 3.0% from $2.09 billion in 2026 to $2.74 billion by 2035 due to the immaturity of the field and the limited number of approved therapies.¹³ The value of the global allogeneic cell therapy manufacturing market, however, is anticipated to expand at a CAGR of 15.0% from 2025 to 2034.¹⁴

Over 365 clinical trial have been registered for many types of allogeneic cell therapies (CAR and non-CAR) targeting a wide range of diseases beyond cancer and autoimmune disorders, including infectious diseases and neurological conditions.¹³ Partnerships, collaborations, and acquisitions have been key to advancing allogeneic cell therapy programs, such as the purchase by Roche of Poseida Therapeutics (allogeneic CAR-T therapies) and the partnership between Cytomel Therapeutics and SunAct Cancer Institute on γδ T cell therapies. Funding of companies developing allogeneic cell therapies has also increased, reflecting growing interest in response to increasing early preclinical and clinical evidence supporting the safety and efficacy of these novel treatments.